Reduced-Dose Radiation Shows Durable Control
Single-arm cohort findings contrast with interim results from NRG-HN005, underscoring ongoing uncertainty around treatment deintensification.
By
Andrea Surnit
May 8, 2026
Clinical Scorecard: Reduced-Dose Radiation Shows Durable Control
At a Glance
Category Detail
Condition Key Mechanisms Deintensified 60-Gy radiotherapy regimen with concurrent cisplatin; intensity-modulated radiotherapy used. Target Population Care Setting
Key Highlights
5-year locoregional recurrence rate of 3.4%. Progression-free survival at 5 years was 86.5%. Overall survival at 5 years was 92.4%. Nodal stage was the only independent factor for progression-free survival. No locoregional recurrences in lower-risk patients treated with radiotherapy alone. Distant recurrence occurred in 7.3% of patients at 5 years. Median time to progression was 1.9 years. Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Prolonged surveillance may be warranted due to late recurrences. Risks
Patient & Prescribing Data
Cisplatin at 30 mg/m² weekly was the preferred systemic therapy due to its efficacy in this patient population.
Clinical Best Practices
Carefully select patients for deintensified treatment approaches. Ensure informed consent regarding treatment risks and benefits, including potential discrepancies in outcomes. Related Resources & Content
